Regeneron posts higher revenue, profit as third-quarter Eylea sales reach $1 billion in US

Headline results for the third quarter:


$1.7 billion (forecasts of $1.6 billion)



$595 million


Note: All changes are versus the prior-year period unless otherwise stated

What the company said:

"Regeneron continues to grow and diversify our business, while continuing to deliver very strong financial results," commented CEO Leonard Schleifer, adding "in addition to Eylea reaching over $1 billion in quarterly US net sales, we also made significant progress with Dupixent, a key driver of future growth, and launched Libtayo, our first immuno-oncology therapy."

Other results:

  • Total Eylea sales: $1.7 billion, up 11 percent
    • Eylea US sales: $1 billion, up 7 percent
  • Dupixent: $263 million, versus $89 million in the prior-year period, including US sales of $220 million
  • Praluent: $80 million, versus $49 million in the prior-year period
  • Zaltrap: $25.4 million, up from $21.7 million in the year-ago period
  • Kevzara: $24.8 million, up from $3 million in the year-ago quarter
  • Collaboration revenue from Sanofi and Bayer: $521 million, up from $481 million in the year-ago period

Looking ahead:

Regeneron currently expects full-year Sanofi collaboration revenue of $430 million to $455 million, down from a prior expectation of $455 million to $485 million.

To read more Top Story articles, click here.